{"date":"2025-01-23","count":3,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6550-2025-01-23-1902-iiomxw","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-01-23","time":"19:02:55","subject":"(更正)公告董事會決議對迪瑞藥業(成都)有限公司「以債轉股」方式增加大陸地區投資","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-01-23 19:02，「(更正)公告董事會決議對迪瑞藥業(成都)有限公司「以債轉股」方式增加大陸地區投資」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6589-2025-01-23-1825-1fb4qj3","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2025-01-23","time":"18:25:34","subject":"本公司研發中產品EG1206A（pertuzumab生物相似藥）接獲美國食品藥物管理局同意進行第三期臨床試驗","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2025-01-23 18:25，「本公司研發中產品EG1206A（pertuzumab生物相似藥）接獲美國食品藥物管理局同意進行第三期臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-01-23-1629-1rtcksk","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-01-23","time":"16:29:52","subject":"公告董事會決議對迪瑞藥業(成都)有限公司「以債轉股」方式增加大陸地區投資","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-01-23 16:29，「公告董事會決議對迪瑞藥業(成都)有限公司「以債轉股」方式增加大陸地區投資」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}